Pretax income is the income that a company earns before paying income taxes. OncoCyte's pretax income for the
three
months ended in Sep. 2024 was $-13.49 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-43.14 Mil.
OncoCyte's pretax margin was -11,733.04%.
During the past 11 years, OncoCyte's highest Pretax Margin was -1653.69%. The lowest was -6085.19%. And the median was -2174.11%.
OncoCyte Pre-Tax Income Historical Data
The historical data trend for OncoCyte's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OncoCyte's Pre-Tax Income
For the Diagnostics & Research subindustry, OncoCyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where OncoCyte's Pre-Tax Income falls into.
OncoCyte Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
OncoCyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte (NAS:OCX) Pre-Tax Income Explanation
OncoCyte's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 11 years, OncoCyte's highest Pretax Margin was -1653.69%. The lowest was -6085.19%. And the median was -2174.11%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of OncoCyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCX has been successfully added to your 